Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany maintains stem cell impetus:

This article was originally published in Clinica

Executive Summary

Germany's Robert Koch Institute (RKI) has granted a third licence for the import of human embryonic stem cells for research. It has authorised senior doctor Wolfgang-Michael Franz from the Munich University Hospital to use imported cells in research on in vitro differentiation of human embryonic stem cells in heart muscles, their purification and enrichment, and functional characterisation. Following their immunological, electrophysiological and pharmacological characterisation, the heart muscle cells will be transplanted in immune-deficient mice so that their potential value in during a heart infarct can be monitored. The RKI made its first import licence award in December 2002 (see Clinica No 1040, p 4).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel